Case Details
- Citation: [2020] SGHC 201
- Case Title: Tiong Sze Yin Serene v HC Surgical Specialists Ltd and another
- Court: High Court of the Republic of Singapore
- Date of Decision: 28 September 2020
- Judge: Chua Lee Ming J
- Coram: Chua Lee Ming J
- Case Number: Originating Summons No 491 of 2020
- Procedural Posture: Application for leave under s 216A(2) of the Companies Act to commence a statutory derivative action; application dismissed with costs; plaintiff appealed against dismissal
- Applicant/Plaintiff: Tiong Sze Yin Serene
- Respondents/Defendants: (1) HC Surgical Specialists Ltd (the “Company”) (2) Dr Heah Sieu Min (“Dr Heah”)
- Legal Area: Companies — statutory derivative action
- Key Statutory Provision: Companies Act (Cap 50, 2006 Rev Ed), s 216A(2)
- Core Substantive Themes: Whether the proposed derivative action is prima facie in the interests of the company; whether the applicant is acting in good faith
- Counsel for Plaintiff/Applicant: Ong Ying Ping and Kenneth Chua Kok Siong (Ong Ying Ping Esq)
- Counsel for First Defendant/Respondent: Tan Chee Meng SC, Paul Loy Chi Syann and Janie Hui (WongPartnership LLP)
- Counsel for Second Defendant/Respondent: Chua Sui Tong and Gan Jhia Huei (Rev Law LLC)
- Judgment Length: 16 pages, 7,910 words
Summary
In Tiong Sze Yin Serene v HC Surgical Specialists Ltd and another [2020] SGHC 201, the High Court considered an application for leave to bring a statutory derivative action under s 216A(2) of the Companies Act. The applicant, Ms Tiong Sze Yin Serene (“the plaintiff”), sought leave to commence proceedings in the name of the listed company, HC Surgical Specialists Ltd (“the Company”), against its Executive Director and CEO, Dr Heah Sieu Min (“Dr Heah”). The plaintiff alleged that Dr Heah breached directors’ duties in connection with the Company’s acquisition-related arrangements involving Julian Ong Endoscopy & Surgery Pte Ltd (“JOES”).
The court dismissed the leave application with costs. Although the judgment is procedural in nature—focused on whether leave should be granted—the decision is substantively important because it addresses two threshold requirements under the statutory derivative regime: first, whether the proposed action is prima facie in the interests of the company; and second, whether the applicant is acting in good faith. The court’s reasoning reflects a cautious approach to derivative litigation, particularly where the narrative includes personal disputes, parallel regulatory and defamation proceedings, and questions about the applicant’s motivations and the evidential basis for the alleged breaches.
What Were the Facts of This Case?
The Company is listed on the Catalist Board of the Singapore Exchange. It operates a medical services group providing endoscopic procedures and general surgery services, with a focus on colorectal procedures. Dr Heah, a surgeon by profession, served as an Executive Director and CEO at all material times.
JOES is operated by Dr Ong Kian Peng Julian (“Dr Ong”), a surgeon. On 1 February 2017, the Company acquired 51% of JOES from Dr Ong for $2,175,000 (the “51% Acquisition”). Under the first sale and purchase agreement (“the 1st SPA”), the Company agreed to purchase the remaining 49% by 1 April 2021 (or another agreed date). The purchase price was to be computed by reference to JOES being valued at ten times its audited profit after tax for the financial year ended 31 May 2020. The 1st SPA also contained “Profit Guarantees” by Dr Ong, covering both the 51% and 49% interests, with Dr Ong required to pay shortfalls if the guaranteed profit after tax attributable to the Company’s interests fell below the guaranteed amounts.
The plaintiff’s involvement in the dispute arose from a personal relationship and subsequent allegations. In December 2016, the plaintiff met Dr Chan, a psychiatrist. The plaintiff alleged that her marriage was then experiencing difficulties. In January 2017, she began an intimate relationship with Dr Chan. Dr Chan was described as a close personal friend of Dr Ong, though he had no role in JOES or the Company. In April 2018, the plaintiff and Dr Chan travelled to Eastern Europe, where, according to the plaintiff, Dr Chan repeatedly urged more adventurous sexual activities. The plaintiff was not interested, but the suggestions led her to question Dr Chan’s sexual proclivities.
While in Prague, the plaintiff accessed Dr Chan’s phone while he slept and found WhatsApp messages between Dr Chan and Dr Ong (the “WhatsApp Messages”). The plaintiff took photographs of these messages. She alleged that the messages revealed, among other things, Dr Chan’s sexual involvement with other women, Dr Ong’s interest in having a foursome involving the plaintiff, and sharing of sexual exploits between Dr Chan and Dr Ong. The plaintiff further alleged that one of the women mentioned in the messages was Dr Ong’s patient. After confronting Dr Chan, the plaintiff insisted he undergo testing for sexually transmitted diseases. The plaintiff’s relationship with Dr Chan ended in May 2018.
On 31 May 2018, Dr Chan filed a police report alleging that the plaintiff demanded $10,000 and threatened to send screenshots of the WhatsApp Messages to his family, and that she did so after he refused. In June 2018, the plaintiff lodged a complaint with the Singapore Medical Council (“SMC”) against Dr Chan and Dr Ong (the “Complaint”), alleging, in broad terms, sexual misconduct and exploitation of vulnerable patients, including allegations that Dr Chan and Dr Ong colluded to take advantage of vulnerable women patients. The plaintiff also forwarded the Complaint to persons she believed were superiors or colleagues of the doctors.
During this period, Dr Ong informed Dr Heah that the plaintiff was making allegations of sexual misconduct against him and Dr Chan. Dr Heah asked to be kept updated and informed his business partner, Dr Chia Kok Hoong (“Dr Chia”), an Executive Director of the Company. Dr Heah and Dr Chia agreed to keep the Board apprised. The Board initially treated the matter as private to Dr Ong and indicated that it would allow SMC investigations to run their course if and when a complaint was lodged.
In July 2018, Dr Ong commenced a defamation action against the plaintiff in the District Court, based on statements in emails sent by the plaintiff to various persons. The plaintiff pleaded defences including justification, qualified privilege, and fair comment. Dr Heah and Dr Chia monitored the situation, reminded Dr Ong of ethical obligations, and considered whether SMC findings could have implications for the Company. When the SMC formally notified Dr Ong of the Complaint in February 2019, Dr Heah updated Dr Chia and the Board, and the Board again agreed to allow SMC proceedings to proceed before reassessing any further course of action.
In July 2019, the Company entered into an investment agreement with Vanda 1 Investments Pte Ltd (“Vanda”), involving $5m in convertible bonds and a share option. The Board intended to use net proceeds for business expansion. JOES performed exceptionally well, contributing a significant portion of revenue. Dr Heah proposed that the Company use part of the proceeds to acquire a further stake in JOES. Negotiations with Dr Ong led to a second sale and purchase agreement dated 3 September 2019 (“the 2nd SPA”), which amended the Company’s obligation under the 1st SPA and replaced the Profit Guarantees under the 1st SPA (the judgment’s truncated extract indicates that the Profit Guarantees were replaced, though the precise replacement terms are not included in the provided excerpt).
What Were the Key Legal Issues?
The central legal issues were the threshold requirements for granting leave under s 216A(2) of the Companies Act. First, the court had to determine whether the proposed derivative action was “prima facie” in the interests of the company. This requirement is not a full trial on the merits; rather, it is a gatekeeping function to prevent misuse of derivative litigation and to ensure that the proposed claim has a reasonable prospect of benefiting the company.
Second, the court had to consider whether the applicant was acting in good faith. Good faith is a distinct requirement from the prima facie interests inquiry. Even where a claim might appear to raise arguable issues, the court may refuse leave if the applicant’s motivations are improper, the application is being used as a vehicle for collateral purposes, or the evidence suggests the applicant is not genuinely pursuing the company’s interests.
In the factual matrix, these issues were intertwined with the broader context: the plaintiff’s personal disputes with Dr Chan, the defamation action, the SMC Complaint, and the Company’s ongoing commercial decisions involving JOES and Dr Ong. The court therefore had to assess whether the plaintiff’s proposed action against Dr Heah related to genuine breaches of directors’ duties, or whether it was driven by other considerations and lacked a sufficiently coherent evidential foundation.
How Did the Court Analyse the Issues?
Although the judgment is concerned with leave, the court’s analysis demonstrates that the statutory derivative mechanism requires more than assertions of wrongdoing. The court approached the leave application by examining the proposed action’s connection to alleged breaches of directors’ duties and by evaluating whether the plaintiff had established a prima facie case that the company would benefit from the litigation. This involves an assessment of the plausibility of the alleged breach, the relevance of the impugned transactions, and whether the claim is likely to lead to a meaningful remedy for the company rather than merely re-litigate disputes between individuals.
On the “interests of the company” requirement, the court’s reasoning reflects that the derivative action is meant to protect corporate interests where the company itself does not act. In this case, the plaintiff’s allegations were tied to the Company’s acquisition-related arrangements with JOES and the role of Dr Heah in relation to those arrangements. The court therefore scrutinised whether the plaintiff’s proposed claims could realistically show that Dr Heah’s conduct caused loss to the company, or that the company’s decision-making was compromised by a breach of duty. The court also considered the commercial context: the Company’s expansion plans, the performance of JOES, and the investment and acquisition decisions that were being made in a structured manner through agreements.
Importantly, the court also considered the timing and surrounding circumstances. The personal and regulatory disputes involving the plaintiff, Dr Chan, and Dr Ong were ongoing during the period leading up to the 2nd SPA. The court had to assess whether these disputes were relevant to the alleged breach of directors’ duties by Dr Heah. The judgment’s extract shows that Dr Heah and Dr Chia had informed the Board of the allegations and had taken steps to monitor developments, while the Board agreed to allow SMC proceedings to run their course. This background tends to support an inference that the Board was aware of the allegations and considered them through a governance lens, rather than ignoring them.
On the “good faith” requirement, the court’s approach indicates that it will look beyond the formal framing of the claim. Where the applicant’s narrative is closely connected to personal conflict and parallel proceedings, the court may be alert to the possibility that the application is being used to pursue private grievances rather than corporate remedies. The plaintiff’s involvement included lodging complaints to the SMC, sending allegations to third parties, and defending herself in a defamation action. The court therefore had to evaluate whether the derivative action was genuinely aimed at vindicating the company’s rights or whether it was, in substance, a continuation of personal disputes.
In refusing leave, the court concluded that the statutory thresholds were not met. While the provided excerpt does not include the full reasoning on each sub-issue (because the judgment text is truncated), the decision’s outcome—dismissal with costs—signals that the court found either that the proposed action was not sufficiently prima facie beneficial to the company, that the applicant did not demonstrate good faith, or that both requirements failed on the evidence presented. The court’s gatekeeping role under s 216A(2) thus operated to prevent the derivative action from proceeding.
From a doctrinal perspective, the case illustrates that statutory derivative actions are not automatic remedies for dissatisfied stakeholders. The court’s analysis underscores that applicants must present a coherent and evidence-backed case that the company stands to gain from the litigation, and must show that their pursuit of the claim is anchored in corporate interests rather than collateral motives.
What Was the Outcome?
The High Court dismissed the plaintiff’s application for leave under s 216A(2) of the Companies Act. The court ordered that the plaintiff pay costs, reflecting that the application did not satisfy the statutory requirements for leave.
The plaintiff subsequently appealed against the dismissal. However, as at the decision date, the practical effect was that the proposed derivative action could not be commenced in the company’s name without further appellate intervention.
Why Does This Case Matter?
This decision is significant for practitioners because it reinforces the strict, threshold nature of leave applications under Singapore’s statutory derivative regime. The court’s focus on whether the proposed action is prima facie in the interests of the company, and whether the applicant is acting in good faith, confirms that the derivative mechanism is designed to protect corporate interests, not to provide an avenue for collateral disputes or speculative litigation.
For corporate litigators and company directors, the case also highlights the importance of governance processes and documentation. The factual background shows that Dr Heah and Dr Chia informed the Board about allegations and that the Board agreed to allow SMC proceedings to run their course. While the plaintiff alleged breaches connected to acquisition arrangements, the court’s refusal of leave suggests that where directors can demonstrate that they engaged with relevant issues through Board-level processes, it may be harder for an applicant to establish a prima facie case of breach at the leave stage.
For law students and researchers, the case is a useful study in how courts apply gatekeeping standards. It demonstrates that “prima facie interests” is not merely a question of whether wrongdoing is alleged; it is a question of whether the proposed claim is likely to benefit the company. Likewise, “good faith” is not presumed and may be assessed in light of the applicant’s broader conduct and motivations, especially where personal disputes and parallel proceedings are part of the factual matrix.
Legislation Referenced
- Companies Act (Cap 50, 2006 Rev Ed), s 216A(2)
Cases Cited
- [2020] SGHC 201
Source Documents
This article analyses [2020] SGHC 201 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.